Nonsmall Cell Lung Cancer Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting nonsmall cell lung cancer clinical trials across 3 countries. Studies span Phase 1, Phase 2, Not Applicable. Top locations include Winston-Salem, North Carolina, United States, Boston, Massachusetts, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Nonsmall Cell Lung Cancer Trials at a Glance

11 actively recruiting trials for nonsmall cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Winston-Salem, Boston, and Chicago. Lead sponsors running nonsmall cell lung cancer studies include Wake Forest University Health Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., and Gazi University.

Browse nonsmall cell lung cancer trials by phase

Treatments under study

About Nonsmall Cell Lung Cancer Clinical Trials

Looking for clinical trials for Nonsmall Cell Lung Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nonsmall Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nonsmall Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Not Applicable

Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC

Nonsmall Cell Lung Cancer
Wen-zhao ZHONG300 enrolled1 locationNCT07626736
Recruiting

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Metastatic Nonsmall Cell Lung CancerNonsmall Cell Lung Cancer, Stage IV
Gazi University400 enrolled2 locationsNCT07394062
Recruiting
Phase 2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Brain MetastasesNonsmall Cell Lung Cancer Stage III
Wake Forest University Health Sciences60 enrolled1 locationNCT05692635
Recruiting
Phase 2

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Nonsmall Cell Lung Cancer Stage IIIUnresectable Non-Small Cell Lung CarcinomaNonsmall Cell Lung Cancer, Stage II
Wake Forest University Health Sciences28 enrolled1 locationNCT05696782
Recruiting
Phase 2

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Nonsmall Cell Lung CancerPerformance Status
Wake Forest University Health Sciences105 enrolled1 locationNCT04253964
Recruiting
Phase 1

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Metastatic Nonsmall Cell Lung Cancer
University of California, Davis40 enrolled1 locationNCT06228482
Recruiting
Phase 1

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Nonsmall Cell Lung Cancer
Dizal Pharmaceuticals190 enrolled1 locationNCT06813365
Recruiting
Not Applicable

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Carcinoma, Non-Small Cell LungSurvivorshipTargeted Therapy+5 more
Massachusetts General Hospital70 enrolled1 locationNCT04900935
Recruiting
Phase 1

TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors

Solid Tumor, AdultNonsmall Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT03778814
Recruiting
Phase 2

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.62 enrolled1 locationNCT06147570